tirzepatide not compounded GLP-1/GIP (Tirzepatide) changer for advanced compound tirzepatide shelf life Compounded
Description
The medication was pulled from the market in 2004 after it was linked to thousands of heart attacks
Tirzepatide activates both GLP-1 and GIP receptors, while semaglutide only activates GLP-1 receptors
In March 2025, the FDA ended enforcement discretion for compounded tirzepatide after determining that no drug shortage exists
Drug Des Devel Ther 2024;18:2951-69
